Design and Development of Nanoparticles Containing α-Mangostin for Wound Application

Objective: The objective of this research was to design and develop nanoparticles containing α-mangostin (α-MG) for wound applications. Material and Methods: The nanoparticles were composed of polycaprolactone (PCL) and Eudragit® S 100 (EDG), with 10% wt of α-MG; wherein, the optimal compositions of the nanoparticles were studied using a mixture-typed simplex lattice design. The amount of PCL (5-20 milligram/milliliter (mg/mL)) and EDG (5-20 mg/mL) were varied, and the effects of the components toward particle size, size distribution, zeta potential; drug content, and drug release were examined. The physicochemical properties of the nanoparticles were analyzed using a zetasizer. The content of α-MG was quantified using High Pressure Liquid Chromatography. Results: It was found that the nanoparticles having different mixtures of PCL and EDG did not affect the physicochemical properties nor the drug content. However, the release of α-MG can be tuned by varying the nanoparticle composition. Formulations with higher EDG showed greater drug release at pH 7.4, because of the polymer dissolution at a specified pH. The composition of the optimized formulation composed of 16.5 mg/mL of EDG and 8.5 mg/mL of PCL. The optimized nanoparticle showed a controlled release profile of up to 12 h, which was superior to the α-MG solution. Conclusion: The developed nanoparticles of PCL and EDG can be considered as a promising platform to deliver α-MG for wound applications.